STAR-TOR - Registry for the Evaluation of the Safety, Tolerability and Efficacy of Temsirolimus (Torisel®), Sunitinib (Sutent®), and Axitnib (Inlyta®) for the Treatment of Subjects With Advanced Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), and Gastro-Intestinal Stroma Tumor (GIST)
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
Both
Carcinoma, Renal Cell, Advanced, Lymphoma, Mantle-Cell, Gastrointestinal Stroma Tumors
Trial Information
STAR-TOR - Registry for the Evaluation of the Safety, Tolerability and Efficacy of Temsirolimus (Torisel®), Sunitinib (Sutent®), and Axitnib (Inlyta®) for the Treatment of Subjects With Advanced Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), and Gastro-Intestinal Stroma Tumor (GIST)
Survival time analysis
Inclusion Criteria:
- Patients with proven tumor of RCC, MCL or GIST by histology.
- Informed consent signed by patient.
Exclusion Criteria:
- Pregnancy
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Safety: absolute and relative incidence of adverse events
Outcome Time Frame:
entire study
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Germany: BfArM (Bundesinstitut fuer Arzneimittel und Medizinprodukte)
Study ID:
3066K1-4407
NCT ID:
NCT00700258
Start Date:
February 2008
Completion Date:
January 2016
Related Keywords:
- Carcinoma, Renal Cell, Advanced
- Lymphoma, Mantle-cell
- Gastrointestinal Stroma Tumors
- Carcinoma
- Carcinoma, Renal Cell
- Lymphoma
- Lymphoma, Mantle-Cell
Name | Location |
|---|
